Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 52-Week High – Should You Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $40.26 and last traded at $40.2850, with a volume of 5890990 shares. The stock had previously closed at $40.18.

Analyst Upgrades and Downgrades

Several research firms have commented on CNTA. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. B. Riley Financial downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Finally, Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Stock Performance

The stock’s 50-day moving average price is $39.68 and its 200-day moving average price is $31.35. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of -22.54 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, equities research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.09% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CNTA. Perceptive Advisors LLC grew its stake in Centessa Pharmaceuticals by 80.2% in the 1st quarter. Perceptive Advisors LLC now owns 5,258,903 shares of the company’s stock valued at $208,884,000 after acquiring an additional 2,341,269 shares during the last quarter. Bank of America Corp DE raised its position in Centessa Pharmaceuticals by 103.5% during the first quarter. Bank of America Corp DE now owns 1,932,406 shares of the company’s stock worth $76,755,000 after acquiring an additional 982,862 shares during the last quarter. Rock Springs Capital Management LP raised its position in Centessa Pharmaceuticals by 8.6% during the first quarter. Rock Springs Capital Management LP now owns 351,828 shares of the company’s stock worth $13,975,000 after acquiring an additional 27,813 shares during the last quarter. Eagle Health Investments LP lifted its holdings in shares of Centessa Pharmaceuticals by 107.8% in the first quarter. Eagle Health Investments LP now owns 214,291 shares of the company’s stock valued at $8,512,000 after purchasing an additional 111,191 shares in the last quarter. Finally, Torno Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at approximately $794,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.